Parkinson's Disease
Conditions
Brief summary
Primary purpose: Fluctuations and dyskinesia evolution in Parkinson's disease patients, one year after initiation of deep brain stimulation, apomorphin pump or duodopa pump Secundary purposes: * Motor complications evolution at 6 months, 2 and 3 years * MDS UPDRS III score at 6 months, 1, 2 and 3 years * non motor complications evolution at 6 months, 1, 2 and 3 years * cognition and psychiatric complications evolution at 6 months, 1, 2 and 3 years * cutaneous and digestive complications at 6 months, 1, 2 and 3 years * neuropathy occurrence at 6 months, 1, 2 and 3 years * medical treatment and Levodopa equivalent dose modifications at 6 months, 1, 2 and 3 years
Interventions
None listed
Sponsors
University Hospital, Strasbourg, France
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Parkinson disease (UKPDSSB criteria) * Patient with fluctuations and/or dyskinesia , who need treatment with deep brain stimulation, apomorphin pump or duodopa pump * MOCA \>20 * patient \>21 years of age * patient who has signed protocol acceptation
Exclusion criteria
* patient who did not give his acceptation for the protocol * patient with another parkinsonian syndrome than Parkinson' s disease * MOCA\<20 * Patient who does not need second line treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| MDS UPDRS IV (Movement Disorder Society - Unified Parkin-son Disease Rating Scale) score improvement | 1 year | Evaluate the evolution of motor fluctuations and dyskinesias at one year in patients. treated with one of the 3 TSLs (bilateral stimulation of the subthalamic nucleus, apomorphine pump and duodopa pump. the higher the score, the more the disease is installed |
Countries
France
Contacts
Primary ContactMathieu ANHEIM
Outcome results
None listed